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Abstract
Background: The postoperative survival rate of patients with esophageal squamous cell carcinoma (ESCC) remains
poor compared with other gastrointestinal cancers. We hypothesized that skeletal muscle loss in the postoperative
acute phase might be a new predictor for long-term prognosis after highly invasive surgery such as ESCC surgery.
Methods: The following items were retrospectively investigated. First, whether skeletal muscle loss occurred in the
postoperative acute phase of ESCC was verified. Second, the preoperative and intraoperative factors involved in skeletal
muscle loss in the postoperative acute phase of ESCC were investigated. Then, whether skeletal muscle loss in the
postoperative acute phase affected long-term prognosis was examined. The medical records of consecutive patients
who underwent radical esophagectomy for ESCC between January 2010 and February 2015 were retrospectively
reviewed; 72 cases were eligible for this study. The total psoas major muscle mass index (TPI) at the level of the third
lumbar vertebra (L3) was measured using computed tomography (CT) before surgery and 3 days after surgery. The
long-term prognosis was estimated by the Kaplan-Meier method and the multivariate logistic regression model.
Results: There was already a significant reduction of TPI in the acute phase up to POD 3 after ESCC surgery in
comparison with the preoperative baseline TPI (P < 0.001). The TPI reduction rate was significantly milder in cases with
less blood loss during surgery and in cases that underwent thoracoscopic esophagectomy than in cases that
underwent open esophagectomy. The 3-year overall survival rate was significantly different between the TPI reduction
rate severe group and the TPI reduction rate mild group.
Conclusion: Skeletal muscle loss occurred even in the postoperative acute phase. Furthermore, it is very significant
that skeletal muscle loss in the postoperative acute phase of ESCC surgery is involved in the long-term prognosis.
Background
Esophageal cancer is the sixth leading cause of cancer-
related mortality worldwide, and squamous cell carcinoma
is a common histological type of esophageal cancer in East
Asian countries [1]. Advanced esophageal cancer (ESCC)
is still a clinically challenging disease that requires a trimo-
dal approach combining surgery, chemotherapy, and
radiotherapy. To achieve it, the multidisciplinary team
should have expertise in pathology, radiology, endoscopy,
medical oncology, surgery, nursing, dietetics, and other
relevant specialists as needed. Despite the advances of
multimodality therapy, radical esophagectomy (subtotal
esophagectomy with two/three-field lymph node dissec-
tion) remains the mainstream treatment for advanced re-
sectable esophageal cancers [2]. Although the surgical
technique and perioperative management for ESCC have
developed, the postoperative survival rate of ESCC re-
mains poor compared with other gastrointestinal cancers
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[3, 4]. Thus, specific prediction markers for the postopera-
tive outcomes of ESCC have been sought for the purpose
of contributing to a better prognosis.
Sarcopenia was defined as the loss of skeletal muscle
volume, skeletal muscle strength, and physical function
in the diagnostic criteria of the European Working
Group on Sarcopenia in Older People [5]. Sarcopenia is
classified into primary sarcopenia and secondary sarco-
penia according to its cause. Primary sarcopenia is sim-
ply caused by aging, and secondary sarcopenia is caused
by activity loss (disuse), disease, or malnutrition [5].
In gastrointestinal cancers, not only the inflammation
and hypercatabolism caused by the cancer itself, but also
the malnutrition caused by organic changes such as a
passage disorder, are likely to lead to skeletal muscle loss
as a secondary sarcopenia. Furthermore, cancer treat-
ments, including surgery, are also considered to cause
skeletal muscle loss due to malnutrition, disuse, and hy-
percatabolism due to the side effects of their invasive-
ness [6, 7].
Recently, there have been many studies on skeletal
muscle loss during the perioperative phase, including in
gastrointestinal cancers. However, most analyses were of
sarcopenia before surgery using the index calculated by
the standard formula, and they reported that it was a
risk factor for postoperative complications and a poor
long-term prognosis [8–13]. Regarding skeletal muscle
loss after surgery, there have been a few studies of skel-
etal muscle loss concerned with postoperative outcomes
only in cancers of organs other than the gastrointestinal
tract [14]. On the other hand, there also have been re-
ports that body composition changes after gastrointes-
tinal cancer surgery, such as body weight loss (BWL)
and skeletal muscle loss, were greater in the postopera-
tive acute phase (around 1 week after surgery) than in
the chronic phase (about 1 or more months after sur-
gery) [14]. In view of the above, we hypothesized that
skeletal muscle loss in the postoperative acute phase
might be a new predictor for long-term prognosis, espe-
cially for highly invasive surgery such as ESCC surgery.
However, to the best of our knowledge, no previous
study has focused on the relationship between skeletal
muscle loss in the postoperative acute phase and postop-
erative outcomes, including long-term prognosis.
In our university hospital, routine computed tomog-
raphy (CT) has been performed on postoperative day
(POD) 3 for all ESCC patients who underwent surgery
to detect postoperative acute complications for more
than 10 years. Thus, many CT image files of the postop-
erative very acute phase of ESCC patients are available
in our hospital. Thus, it was possible to analyze skeletal
muscle loss using them in comparison with baseline
image files. In this study, the following items were retro-
spectively investigated. First, whether skeletal muscle
loss occurred in the postoperative acute phase of ESCC
was verified. Second, the preoperative and intraoperative
factors involved in skeletal muscle loss in the postopera-
tive acute phase of ESCC were investigated. Then,
whether skeletal muscle loss in the postoperative acute
phase affected the long-term prognosis was examined.
Methods
Patients
The medical records of consecutive patients who under-
went radical esophagectomy (subtotal esophagectomy
with two/three-field lymph node dissection) for ESCC at
the Okayama University Hospital (Okayama, Japan) from
January 2010 to February 2015 were retrospectively
reviewed. A total of 273 ESCC cases without evidence of
distant metastases underwent radical esophagectomy. To
investigate advanced resectable ESCC, cases with clinical
stage over II were selected, excluding those with T4b and
supraclavicular lymph node metastasis and other organ
metastasis at the time of treatment initiation. Four pa-
tients after definitive chemoradiotherapy were excluded.
Nine patients with unresectable or residual cancer (R1/2)
at operation were also excluded. To eliminate differences
in surgical invasiveness, the operative procedure was
limited to radical esophagectomy with gastric tube recon-
struction; other procedures (two-stage operation, recon-
struction with jejunum/colon) were excluded. Cases that
underwent combined resection of other organs with can-
cer were also excluded. In addition, 30 cases were ex-
cluded because of insufficient CT data. Thus, 72 cases
were eligible for this study (Fig. 1).
Surgical procedures
Esophagectomy with two/three-field lymph node dissec-
tion was performed. We had been performing open
esophagectomy (OE) until June 2011 when thoraco-
scopic esophagectomy in the prone position (TEPP) was
introduced. After that, we have been performing TEPP
as standard procedure. In this study, 22 cases underwent
OE, and 50 cases underwent TEPP. We also investigated
the relationship between those surgical procedures and
skeletal muscle loss, which may be an invasive marker.
Subsequently, abdominal lymphadenectomy and gastric
conduit reconstruction were performed under laparot-
omy or hand-assisted laparoscopic surgery (HALS). The
details of the surgical techniques of radical esophagec-
tomy have been reported [15]. Data of the surgical pro-
cedure, operative time, amount of blood loss, and
infusion volume were recorded as operative factors.
Postoperative management
During this period, there was no change in postoperative
care, including drugs administered (methylprednisolone,
antibiotics, proton pump inhibitors, catecholamine). The
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patients were admitted to the intensive care unit (ICU)
on mechanical ventilation after radical esophagectomy.
The patients were extubated on POD 1 if they had no
problems on chest X-ray, blood examinations, and bron-
choscopy. On POD 3, CT was performed to detect post-
operative acute complications. If there were no serious
findings on CT, and the patient’s course was good, the
patient could be discharged from the ICU.
CT analysis
The preoperative baseline CT examination was taken
within 1 week before surgery (at the time admission for
surgery) for the cases with preoperative therapy or pre-
operative sarcopenia and taken within 1 month before
surgery for the cases without both preoperative therapy
and preoperative sarcopenia. The original purpose of the
CT examination in the postoperative acute phase (POD
3) was to detect postoperative complications such as
pneumonia, anastomotic leakage, and venous thrombosis
for all patients who underwent ESCC surgery. Therefore,
the changes in skeletal muscle mass could be analyzed
using the CT images of the postoperative acute phase
and preoperative baseline images before surgery.
Measurement of skeletal muscle loss
Following previously published reports about sarcope-
nia, skeletal muscle mass was measured at the level
of the third lumbar vertebra (L3) with CT images. Al-
though there are many reports using total skeletal
muscle mass at the L3 level [11, 13, 16–20], only the
psoas muscle was measured to as much as possible
exclude the effects of edema in the postoperative
acute phase [6]. The images were evaluated using a
CT image analysis system (Synapse Vincent, Fujifilm
Medical, Tokyo, Japan). The iliopsoas area at the L3
Fig. 1 Case flow chart. cStage, clinical stage (UICC8th); CRT, chemoradiation; R, residual tumor
Fig. 2 Measurement of skeletal muscle mass at the level of the third
lumbar vertebra (L3) with CT images. Green field, total muscle mass;
yellow field, psoas muscle mass
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level was measured using Hounsfield units (HU) of −
29 to + 150 (Fig. 2). The quantity of skeletal muscle
was evaluated with the total psoas major muscle mass
index (TPI). The TPI was defined by normalizing the
cross-sectional areas of the bilateral psoas major mus-
cles for height (cm2/m2). Furthermore, the change in
the skeletal muscle loss from the preoperative state to
the postoperative acute phase was analyzed using the
change of TPI. The TPI reduction rate was calculated
using the formula (postoperative TPI-preoperative
TPI)/preoperative TPI × 100.
Analyzed parameters
Skeletal muscle loss in the acute phase after ESCC surgery
was retrospectively analyzed. For that analysis, the median
TPI reduction rate was defined as the cutoff value to div-
ide patients into the TPI reduction rate mild group and
the TPI reduction rate severe group. The preoperative fac-
tors (age, blood data, tumor factors, preoperative sarcope-
nia, etc.) and intraoperative factors (surgical procedure,
blood loss, operative time, etc.) concerned with skeletal
muscle loss in the acute phase after ESCC surgery were in-
vestigated. Furthermore, the relationship between skeletal
Table 1 Patients’ characteristics
Characteristic Number of patients (%) n = 72
Age, y, median (IQR) 66 (43 - 83)
Sex, n (%)
Male 65 (90%)
Female 7 (10%)
ASA, n (%)
1, 2 65 (90%)
≥ 3 7 (10%)
Preoperative sarcopeniab, n (%)
Sarcopenic 64 (89%)
Nonsarcopenic 8 (11%)
Tumor location, n (%)
Ce 4 (6%)
Ut 13 (18%)
Mt 30 (42%)
Lt 23 (32%)
Ae 2 (3%)
Operative procedure, n (%)
Open esophagectomy 22 (31%)
Thoracoscopic esophagectomy 50 (69%)
Preoperative therapy, n (%)
None 17 (24%)
Chemotherapy 54 (75%)
Chemoradiotherapy 1 (1%)
Postoperative therapy (including adjuvant therapy), n (%)
No 22 (31%)
Yes 50 (69%)
pStage, n (%)
< pStage III 36 (50%)
≥ pStage III 36 (50%)
TPI (cm2/m2), median (IQR)
Preoperative TPI 4.63 (3.74 - 5.77) P = 0.116a
Postoperative TPI 4.28 (3.62 - 5.28)
TPI total psoas major muscle mass index, pStage pathological stage (UICC 8th), ASA the American Society of Anesthesia physical status, IQR interquartile range,
aWilcoxon rank-sum test, bAccording to the definition of Prado [22]
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muscle loss in the acute phase after ESCC surgery and
long-term prognosis was investigated together with other
clinicopathological parameters including preoperative
sarcopenia.
Statistical analysis
Clinicopathological factors were noted according to
the Union for International Cancer Control (UICC)
Tumor Nodes Metastasis (TNM) Classification of Ma-
lignant Tumors, 8th edition [21]. To evaluate the dif-
ferences between the two groups, continuous variables
were assessed using the Wilcoxon rank-sum test, and
categorical variables were evaluated using Fisher’s
exact test. Differences were considered significant
when the P value was < 0.05. Kaplan-Meier analyses
were also used to estimate the cumulative survival of
patients. To identify the preoperative prognostic fac-
tors for 3-year survival, all variables with P < 0.05 on
the univariate analysis were included in the multivari-
ate logistic regression model. All analyses were per-
formed using the JMP version 14 statistical analysis
software (SAS Institute, Cary, NC, USA).
Results
Clinicopathological characteristics of patients with ESCC
Of the 72 ESCC cases, 65 were male, and 7 were fe-
male. Physical status according to the ASA classifica-
tion was grade 1 or 2 in 65 cases and grade 3 in 7
cases. The presence of preoperative sarcopenia was
defined according to the standard from Prado’s report
[22], and the cutoff value of the skeletal muscle mass
index was determined to be 52.4 for males and 38.5
for females. Patients whose values were less than or
equal to the cutoff values were defined as having sar-
copenia, and 64 cases were diagnosed with preopera-
tive sarcopenia. Of the 72 cases, 55 received
preoperative therapy, and 17 did not. Fifty-four cases
received preoperative chemotherapy, and one case re-
ceived preoperative chemoradiotherapy. The surgical
procedure was OE with right thoracotomy in 22 cases
and TEPP as minimally invasive surgery MIS in 50
cases. Half of the cases were diagnosed with patho-
logical stage III or higher (Table 1).
Change of TPI in the acute phase after ESCC surgery
First, whether skeletal muscle loss occurred in the acute
phase after ESCC surgery was examined. Out of the 72
cases, 59 cases’ (81.9%) TPI was decreased in the acute
phase up to POD 3 after ESCC surgery, and the median
TPI reduction rate was − 4.4%. There was already a sig-
nificant change in of TPI in the acute phase up to POD
3 after ESCC surgery in comparison with the preopera-
tive baseline TPI (P < 0.001) (Fig. 3).
Associations between patient characteristics and skeletal
muscle loss in ESCC surgery
The median TPI change rate (− 4.4%) was used as the cut-
off value to divide patients into the TPI reduction rate
Fig. 3 Change of TPI in the acute phase after ESCC surgery from preoperative baseline TPI (n = 72). TPI, total psoas major muscle mass index;
*median (25%, 75%)
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mild group (n = 36) and the TPI reduction rate severe
group (n = 36). The factors involved in skeletal muscle loss
in the acute phase of ESCC surgery were examined. TPI
reduction rate was significantly milder in cases of less
blood loss during surgery (P = 0.0087) and in cases of
TEPP than in cases of OE (P = 0.0407) (Table 2).
Associations between clinicopathological factors
including the TPI reduction rate and long-term survival
after ESCC surgery
The 3-year overall survival rate was significantly lower
in the TPI reduction rate severe group than in the
TPI reduction rate mild group (P = 0.0128). No sig-
nificant difference between the two groups about
progression-free survival (Fig. 4a, b). On the other
hand, no significant difference between the two
groups about with or without sarcopenia (Fig. 4c, d).
Of the patients’ characteristics, surgical factors, and
TPI reduction rate, the TPI reduction rate was an in-
dependent prognostic factor (P = 0.0296), along with
pStage (P = 0.0039) and the presence of preoperative
therapy (P = 0.0137) (Tables 3 and 4).
Discussion
First, this study showed that skeletal muscle loss oc-
curred in the very acute phase after ESCC surgery.
Skeletal muscle loss has been known to easily occur
in the postoperative period due to hypercatabolism,
disuse, and malnutrition. In addition, there have been
some reports of skeletal muscle loss in the postopera-
tive relatively acute phase (7 to 10 days after surgery)
in other gastrointestinal cancers [23, 24]. Even so, it
was surprising that skeletal muscle loss already oc-
curred on POD 3 after ESCC surgery.
Table 2 Correlations between characteristics and sarcopenia in patients undergoing radical esophagectomy
Variable Total cases TPI reduction rate mild group TPI reduction rate severe group P value
Total cases, n (%) 72 (100) 36 (50%) 36 (50%) -
Age at RE (y), median (IQR) 66 (43 - 83) 66 (55 - 83) 66 (44 - 82) 0.9380a
ASA, n (%) 0.6908b
1, 2 65 (90%) 33 (92%) 32 (89%)
≥ 3 7 (10%) 3 (8%) 4 (11%)
Preoperative sarcopeniad, n (%) 0.4533b
Sarcopenic 64 (89%) 33 (92%) 31 (86%)
Nonsarcopenic 8 (11%) 3 (8%) 5 (14%)
Tumor location, n (%) 0.5798c
Ce/Ut 17 (24%) 10 (28%) 7 (19%)
Mt/Lt/Ae 55 (76%) 26 (72%) 29 (81%)
pStage, n (%) 0.3450b
< pStage III 36 (50%) 21 (58%) 15 (42%)
≥ pStage III 36 (50%) 15 (42%) 21 (58%)
Preoperative therapy, n (%) 0.5675c
None 17 (24%) 8 (22%) 9 (25%)
Chemotherapy 54 (75%) 28 (78%) 26 (72%)
Chemoradiotherapy 1 (1%) 0 (0%) 1 (3%)
Postoperative therapy, n (%) 0.5675c
None 17 (24%) 8 (22%) 9 (25%)
Chemotherapy 51 (75%) 28 (78%) 26 (72%)
Chemoradiotherapy 1 (1%) 0 (0%) 1 (3%)
Operative procedure, n (%) 0.0407b
Open esophagectomy 22 (31%) 7 (19%) 15 (42%)
Thoracoscopic esophagectomy 50 (69%) 29 (81%) 21 (58%)
Blood loss (ml), median (IQR) 330 (150 - 510) 230 (110 - 405) 370 (255 - 723.75) 0.0087a
Operative time (min), median (IQR) 616.5 (553.5 - 698) 622 (540.75 - 728.5) 610.5 (559.25 - 676.5) 0.4885a
TPI total psoas major muscle mass index, RE radical esophagectomy, IQR interquartile range, ASA the American Society of Anesthesia physical status, pStage
pathological stage (UICC 8th), aWilcoxon rank-sum test, bFisher’s exact test, cChi-square test, dAccording to the definition of Prado [22]
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Fig. 4 Overall survival curve of the groups with mild and severe reduction of the TPI (a). Progression-free survival curve of the groups with mild
and severe reduction of the TPI. TPI, total psoas major muscle mass index (b). Overall survival curve of the groups with and without sarcopenia
(c). Progression-free survival curve of the groups with and without sarcopenia (d)
Table 3 Univariate logistic regression analysis of factors predicting overall survival in patients undergoing radical esophagectomy
Variable P value Odds ratio 95% CI
Pre-op Sarcopeniaa 0.5259 0.60 0.13 - 3.19
TPI reduction rate severe group 0.0074* 4.43 1.47 - 15.3
Age ≥ 66 y 0.0942 2.57 0.86 - 8.86
≥ ASA 3 0.0109* 8.33 1.62 - 62.47
Pre-op Albumin < 3.6 g/dL 0.7550 1.33 0.17 - 7.46
No preoperative therapy 0.0492* 3.16 1.00 - 10.21
No postoperative therapy 0.5367 0.72 0.25 - 2.03
Pre-op BMI < 18.5 kg/m2 0.3262 0.47 0.07 - 2.00
Open or TEPP 0.1053 2.45 0.83 - 7.33
Open or HALS 0.2610 1.84 0.63 - 5.35
LN dissection field (2-field / 3-field) 0.5692 1.36 0.48 - 4.15
Blood loss ( > 330 ml) 0.4524 1.49 0.53 - 4.29
Operation time ( > 616 min) 1.0000 1.0000 0.35 - 2.83
≥ pStage III 0.0012* 6.40 2.02 - 24.87
Pre-op preoperative, TPI total psoas major muscle mass index, ASA the American Society of Anesthesia physical status, BMI Body mass index, TEPP Thoracoscopic
esophagectomy in the prone position, HALS Hand-assisted laparoscopic surgery, LN lymph node, pStage pathological stage (UICC 8th), aAccording to the definition
of Prado [22], *p value <0.05
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Although the hypercatabolic phase induced by sur-
gical invasion starts on POD 2 and lasts 3–8 days
[25–28], and skeletal muscle loss due to disuse is also
known to occur even after a few days of bed rest
[29], malnutrition is not seen in the postoperative
acute phase. Thus, it was thought that hypercatabo-
lism and disuse might be the causes of skeletal
muscle loss in that phase. According to the results of
the present study, skeletal muscle loss in the postop-
erative acute phase might strongly reflect the hyperca-
tabolism induced by surgical invasion because the TPI
reduction rate was significantly related to intraopera-
tive blood loss as a universal index of surgical inva-
sion. On the other hand, the TPI reduction rate was
significantly milder after TEPP than after OE. Al-
though this might be one of the findings indicating
the lesser invasiveness of TEPP, there was also an-
other possibility: that TEPP as a painless procedure
could maintain the postoperative patient’s physical ac-
tivity and prevent the disuse followed by skeletal
muscle loss. Based on the present study, it is difficult
to clarify which was the main cause, hypercatabolism
or disuse, and further investigation, such as bio-
impedance analysis, is needed. However, in any case,
the TPI reduction rate could be a useful parameter to
identify the appropriate surgery for patients, and it might
be an indicator showing the advantage of TEPP. Further
studies are needed to determine whether thoracoscopic
surgery is more useful than open surgery in esophageal
cancer, and the results of ongoing clinical research of the
Japan Clinical Oncology Group (JCOG 1409) are expected
to clarify this point.
The core aspect of the present study is that, to the
best of our knowledge, it is the first report showing
the effect of skeletal muscle loss in the acute phase
after surgery on the long-term prognosis of ESCC. Al-
though there have been some reports that periopera-
tive skeletal muscle loss was a prognostic predictor
after surgeries for cancers including ESCC [8–14, 30],
they examined skeletal muscle loss in the preoperative
phase or the postoperative chronic phase (about 1 or
more months after surgery). Surprisingly, in the
present study, the TPI reduction rate on POD 3 after
ESCC surgery was an independent long-term pre-
dictor of prognosis that was as significant as
pathological stage and neoadjuvant treatment. Thus,
skeletal muscle loss, even in the acute phase, might
have a certain effect on the long-term prognosis.
Therefore, in order to improve patients’ prognosis
after surgery for esophageal cancer, the early postopera-
tive phase multidisciplinary team approaches, such as
nutritional therapy and physical therapy, would be im-
portant to prevent skeletal muscle loss, similar to the
preoperative intervention in previous reports [31–33].
On the other hand, preoperative sarcopenia was also
pointed out in 89% of this study’s cohort. However, it
was not found to be associated with the long-term prog-
nosis despite previously published reports [30]. The rea-
son for it might be that most cases in this study had
sarcopenia, and there was no statistical difference with
the TPI reduction rate about with or without sarcopenia.
Furthermore, as an operative procedure, it might be a
good option to select thoracoscopic surgery from the
viewpoint of skeletal muscle loss using the TPI reduction
rate as a new parameter of invasiveness or disuse.
Of course, there were several limitations in this study.
This was a retrospective, small cohort study conducted
at a single center only with CT image analysis. In
addition, this study recruited more males than females.
In the future, a large-scale investigation adding other
analytical methods is needed.
Conclusion
This is the first study that focused on the change of skel-
etal muscle volume between the preoperative phase and
the postoperative early phase of esophageal cancer sur-
gery. Skeletal muscle loss was an independent prognostic
factor, along with pStage and the presence of preopera-
tive therapy. It is very important that skeletal muscle loss
in the postoperative acute phase was found to be related
to long-term prognosis.
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